2 recruiting, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Lei Zheng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors BSI-082, Trastuzumab deruxtecan - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | Lei Zheng | 57 | 2026-01-26 | 2026-10-15 |
| A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer Tislelizumab, SX-682 - Pancreatic Cancer | Phase 2 | Recruiting | Lei Zheng | 25 | 2023-11-08 | 2026-10-07 |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Pembrolizumab, Defactinib - Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | Lei Zheng | 28 | 2019-06-04 | 2026-02-04 |
Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Neoplasm Metastasis (1)
defactinib (1) · pembrolizumab (1) · tislelizumab (1) · trastuzumab deruxtecan (1)
United States (3)
Arsen Osipov, MD (1) · John Sarantopoulos, MD (1)